- Home
- SSY vs RNAZ Comparison
SSY vs RNAZ Comparison
Compare SSY & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSY
- RNAZ
- Stock Information
- Founded
- SSY 1959
- RNAZ 2016
- Country
- SSY United States
- RNAZ United States
- Employees
- SSY N/A
- RNAZ N/A
- Industry
- SSY Hospital/Nursing Management
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SSY Health Care
- RNAZ Health Care
- Exchange
- SSY Nasdaq
- RNAZ Nasdaq
- Market Cap
- SSY 6.2M
- RNAZ 6.1M
- IPO Year
- SSY N/A
- RNAZ 2021
- Fundamental
- Price
- SSY $0.97
- RNAZ $8.69
- Analyst Decision
- SSY
- RNAZ Strong Buy
- Analyst Count
- SSY 0
- RNAZ 1
- Target Price
- SSY N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- SSY 88.5K
- RNAZ 27.7K
- Earning Date
- SSY 05-13-2025
- RNAZ 08-13-2025
- Dividend Yield
- SSY N/A
- RNAZ N/A
- EPS Growth
- SSY N/A
- RNAZ N/A
- EPS
- SSY 0.25
- RNAZ N/A
- Revenue
- SSY $31,094,000.00
- RNAZ N/A
- Revenue This Year
- SSY N/A
- RNAZ N/A
- Revenue Next Year
- SSY N/A
- RNAZ N/A
- P/E Ratio
- SSY $4.08
- RNAZ N/A
- Revenue Growth
- SSY N/A
- RNAZ N/A
- 52 Week Low
- SSY $0.62
- RNAZ $6.15
- 52 Week High
- SSY $1.91
- RNAZ $905.52
- Technical
- Relative Strength Index (RSI)
- SSY 54.43
- RNAZ 52.45
- Support Level
- SSY $0.87
- RNAZ $8.04
- Resistance Level
- SSY $1.10
- RNAZ $9.70
- Average True Range (ATR)
- SSY 0.07
- RNAZ 0.64
- MACD
- SSY 0.01
- RNAZ 0.29
- Stochastic Oscillator
- SSY 50.65
- RNAZ 57.26
About SSY SunLink Health Systems Inc.
SunLink Health Systems Inc is engaged in providing retail pharmacy services. The company operates its business through segments namely the Healthcare Services segment and Pharmacy segment. The Healthcare Services segment includes subsidiaries that own and operate licensed-bed, acute care hospitals, which includes bed geriatric psychology unit, and nursing home; own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land; and provides information technology to outside customers. The Pharmacy segment, which is the key revenue generator is composed of retail pharmacy products and services that are conducted in rural markets; institutional pharmacy services; pharmacy services; and durable medical equipment.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.